**COVID- 19 Studies**

**CATCO Trial:** A Multi-centre, Adaptive, Randomized, open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients

- **PI:** Dr. Nelson Lee (ID Research) and Dr. Wendy Sligl
- **Study Sponsor:** Sunnybrook Research Institute – Toronto
- **Interventional Randomized Trial** to evaluate the clinical efficacy and safety of medications, relative to the control arm, in patients hospitalized with COVID-19.

**SPRINT-SARI:** Short Period Incidence Study of Severe Acute Respiratory Infection

- **PI:** Dr. Oleksa Rewa
- **Study Coordinator:** Lorena McCoshen
- **Study Sponsor:** Sunnybrook Research Institute – Toronto
- **Prospective and Retrospective Observational Study** to establish a research response capability for future epidemics or pandemics through a global SARI observational study

**ECMO-CARD:** Extracorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease

- **PI:** Dr. Gurmeet Singh
- **Study Coordinator:** Nadia Baig
- **Study Sponsor:** The Prince Charles Hospital – Australia
- **Prospective Observational Study** to describe clinical features severity of pulmonary dysfunction; incidence of ICU admission and use of mechanical ventilation and ECMO; and survival of patients with COVID-19

**Laboratory markers in COVID-19**

- **PI:** Dr. Wendy Sligl

**Prospective Observational Study** to determine if HLH markers can be used for following disease activity and response to immunomodulation by correlating them with patient clinical courses

**Immune Response to COVID-19**

- **PI:** Dr. Wendy Sligl

**Prospective Observational Study** to characterize immune responses in individuals with mild versus the severe forms of the disease.

---

**ONGOING STUDIES**

**BALANCE Trial:** Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): Randomized control trial

- **PI:** Dr. Wendy Sligl
- **Study Coordinator:** Lorena McCoshen
- **Study Sponsor:** Sunnybrook Research Institute – Toronto
- **Interventional Randomized Concealed allocation Trial** of shorter duration (7 days) versus longer duration (14 days) antibiotic treatment for patients with bloodstream infections.

**LOVIT Trial:** Lessening Organ Dysfunction with VITamin C

- **PI:** Dr. Oleksa Rewa
- **Study Coordinator:** Lorena McCoshen
- **Study Sponsor:** Centre de recherche du Centre hospitalier – University of Sherbrooke (Quebec)
- **Interventional Parallel Blinded Randomized Controlled Trial** determining if the administration of vitamin C decreases the harmful effects of infections on organs and improve health status more quickly than placebo.

**FORECAST Study:** Frailty, Outcomes, Recovery and Care Steps of Critically Ill Patients

- **PI:** Dr. Oleksa Rewa
- **Study Coordinator:** Nadia Baig
- **Study Sponsor:** Queen’s University – Kingston, Ontario
- **Prospective Observational Study**, determining how and when to measure frailty in ICU patients, to understand how the care received affects the outcomes of those who are or become frail, and determine how to improve outcomes of those who are frail.

**COHO Study:** Critical Care Outcomes of Hematologic Oncology Patients

- **PI:** Dr. Sean Bagshaw
- **Study Coordinator:** Nadia Baig
- **Study Sponsor:** Mount Sinai Hospital – Toronto, Ontario
- **Prospective Observational Study** – to evaluate determinants of ICU and 1-year survival and physical disability in critically ill adults with hematologic malignancy and hematopoietic cell transplantation

For more information about our research contact Dr. Oleksa Rewa, Director of Research at 780-248-1256, Nadia Baig, Research Manager at 780-492-3817, or visit our website at [www.ualberta.ca/critical-care/research](http://www.ualberta.ca/critical-care/research)